Rebecca Morrison

Rebecca Morrison

Auto-generated profile, based on publicly available information

Rebecca Morrison

Independent Researcher, Berlin, Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
ASAnna Sippel
Anna Sippel
KRKarin Riemann-Lorenz
Karin Riemann-Lorenz
JSJutta Scheiderbauer
Jutta Scheiderbauer
IKIngo Kleiter
Ingo Kleiter
RMRebecca Morrison
Rebecca Morrison
Christoph HeesenChristoph Heesen
Christoph Heesen
Background: Besides coping with a disease with many uncertainties, people with relapsing-remitting multiple sclerosis face complex decisions concerning disease-modifying therapies (DMTs). In an interview study, we aimed to assess patients’ experiences with DMTs. Methods: Problem-centred interviews were conducted with 50 people with relapsing-remitting multiple sclerosis in Germany using maximum variation sampling and covering all licensed DMTs. Data were analysed thematically using deductive and inductive categories. Results: 47 of 50 patients had treatment with at least one of the approved DMTs. The main themes were: (1) starting a DMT, (2) switching to another DMT, (3) discontinuing a DMT, and (4) multiple sclerosis without starting a DMT. Different intercorrelated factors influenced the decision-making processes for or against a DMT. Individual experiences with DMTs in daily life contained the effort in administration, success, and failure of DMTs, coping strategies and well-being without DMTs. The decision-making process for or against a DMT and the use of those treatments can be understood as a constant, continually shifting process, complicated by different factors, which change over time. Experiences with DMTs were characterized by attempts to handle uncertainty and to (re)gain control and integrate adaptivity into one’s life. Conclusions: The study provides a rich and nuanced amount of patients’ experiences with DMTs. The findings demonstrate the importance for practitioners to look at current life circumstances of patients with multiple sclerosis when recommending a DMT and to promote and enable patients to make informed decisions.

8 June 1998
Verified
Conference Paper
Open access
NMN.E. McGruer
N.E. McGruer
PZP.M. Zavracky
P.M. Zavracky
SMS. Majumder
S. Majumder
GAG.G. Adams
G.G. Adams
RMR. Morrison
R. Morrison

2 March 2017 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
RMRebecca Morrison
Rebecca Morrison
JKJansher Khan
Jansher Khan
PGPeter Galloway
Peter Galloway
JMJane McNeilly
Jane McNeilly
SASyed Faisal Ahmed
Syed Faisal Ahmed
DPDawn Penman
Dawn Penman
We studied the relationship between adrenal weight and postmortem cortisol level in cases of infant death, and examined use of these measurements in adrenal insufficiency. We analyzed procurator-fiscal postmortem reports in the West of Scotland over a three year period. Combined adrenal weight was expressed as percentage of total body weight (%TBW). Of 106 cases, median (5th, 95th) %TBW was 0.056 (0.025, 0.23) and median plasma cortisol was 8.4 ug/dl (1.0, 47.1). There was no correlation between %TBW and plasma cortisol (r = 0.09, p = 0.4). The lowest and highest plasma cortisol quartile had medians of 1.9 ug/dl (1.0, 3.4) and 34.3 ug/dl (17.3, 71.5), respectively. Infection was present in 6 cases (23.1%) in the lowest quartile and in 16 cases (61.5%) in the highest quartile (p = 0.01). Our results highlight the difficulty in interpretation of cortisol at postmortem and suggest that adrenal weight measurement alone may be insufficient for diagnosis of adrenal insufficiency.

1 September 2020
Verified
Conference Paper
Open access
PDF file
SWStephanie Weitemeyer
Stephanie Weitemeyer
SDStephanie Draeger
Stephanie Draeger
RMRebecca Morrison
Rebecca Morrison
LHLehang Huynh
Lehang Huynh
AGAshok K. Goel
Ashok K. Goel
MSMartha Sloan
Martha Sloan